Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Total Non-Current Liabilities (2020 - 2024)

Climb Bio filings provide 5 years of Total Non-Current Liabilities readings, the most recent being $5.3 million for Q4 2024.

  • Quarterly Total Non-Current Liabilities rose 86.31% to $5.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2024, up 86.31% year-over-year, with the annual reading at $5.3 million for FY2024, 86.31% up from the prior year.
  • Total Non-Current Liabilities hit $5.3 million in Q4 2024 for Climb Bio, up from $3.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $7.9 million in Q2 2022 and bottomed at $2.8 million in Q4 2023.
  • Average Total Non-Current Liabilities over 5 years is $4.8 million, with a median of $4.4 million recorded in 2023.
  • The largest annual shift saw Total Non-Current Liabilities surged 96.9% in 2021 before it plummeted 54.63% in 2023.
  • Climb Bio's Total Non-Current Liabilities stood at $3.1 million in 2020, then surged by 96.9% to $6.0 million in 2021, then grew by 4.08% to $6.3 million in 2022, then plummeted by 54.63% to $2.8 million in 2023, then soared by 86.31% to $5.3 million in 2024.
  • Per Business Quant, the three most recent readings for CLYM's Total Non-Current Liabilities are $5.3 million (Q4 2024), $3.4 million (Q3 2024), and $3.7 million (Q2 2024).